Provenance Record

Strong, substantive News piece (~937 words, in range). Clear structure: Overview / What We Know / A New Regulatory Pathway / What We Don't Know / Why It Matters. Appropriately hedged on durability, free-access scope, and patient-identification challenges. The internal cross-reference to the Envoy Medical cochlear-implant article (2026-04-07) provides legitimate editorial continuity.

Read all 4 local snapshots from sources/2026-04/fda-approves-regenerons-otarmeni-as-first-gene-therapy-for-genetic-hearing-loss-with-the-drugmaker-pledging-free-access-in-the-us/ (all 200 OK; CNN redirected to edition.cnn.com, captured correctly). FDA (source-0): VERIFIED — April 23 2026 approval date, drug name, Regeneron, indication, first gene therapy for genetic hearing loss, tied for fastest BLA, dual AAV mechanism, 80% improved hearing in 20 evaluable patients, 'not expected in the natural history' quote, sixth CNPV approval, first gene therapy under CNPV. NOT FOUND: 'first cell or gene therapy' (FDA says 'first gene therapy product' without 'cell or'); 2025 launch date for the voucher program. Regeneron (source-1): VERIFIED — OnPath with OTARMENI program, free for clinically eligible U.S. patients, Phase 1/2 CHORD trial with 20 patients aged 10mo-16y, 10 unilateral / 10 bilateral, the listed adverse reactions and surgical risks (Regeneron uses 'partial facial paralysis or weakness' for what the article calls 'facial nerve paresis' — equivalent), all four FDA designations, Yancopoulos quotes. CONTRADICTED on Yancopoulos's title (Regeneron lists 'Board co-Chair, President and Chief Scientific Officer'; article says 'co-founder and chief scientific officer'). PARTIALLY VERIFIED on uncovered costs (release mentions 'administration' costs only, no enumerated list). CNN (source-2): VERIFIED — '5 of 12 followed at least 11 months hearing essentially restored to normal'; '16 of 20 with improvements about five months after treatment'. NOT FOUND in CNN — 'reduces fidelity' framing; cochlear-implant comparison handled differently. NBC (source-3): VERIFIED — ~50 babies/year affected, 16/20 children showed improvements, only existing intervention is cochlear implant, 'on 24/7 and doesn't rely on batteries' Shearer quote, 'reduces the fidelity of the sound' Shearer quote. NBC does NOT contain the '5 of 12' figure or the 'five months after treatment' timing — those are in CNN. The article has therefore SWAPPED the CNN and NBC attributions on three discrete claims.

Underlying medical and regulatory facts are accurate (drug name, approval date, mechanism, trial design, adverse-reaction list, 80% efficacy headline, surgical risks, FDA designations, free-access program). The problems are all attribution errors: three claims are pointed at the wrong outlet (CNN<->NBC swap), Yancopoulos's title doesn't match the cited press release, the 'cell or' qualifier broadens the FDA's actual statement, the 2025 voucher-launch year is unsourced in the cited FDA URL, and the enumerated cost categories go beyond Regeneron's wording.

Medically and regulatorily sound article on a real, important approval. The writing is clean and the structure is exemplary. But six discrete attribution problems — three of them substantive (CNN/NBC swaps that put quotes in the wrong reporters' mouths) — must be corrected before publication. Once attributions are fixed, this is a clean Biotech & Medicine News piece.